Abstract 126P
Background
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide and its incidence is steadily rising. Recently, immune-checkpoint inhibitors have revolutionized the management of HCC and combination of atezolizumab and bevacizumab has been shown to improve overall survival. We performed a molecular and cellular characterization of the tumour microenvironment that plays a crucial role in the development of HCC.
Methods
We performed a sequential treatment with anti-PD-L1 atezolizumab in combination with anti-VEGF bevacizumab for 6 days followed by tyrosine kinase inhibitor (TKI) lenvatinib for additional 6 days on HCC cell lines (HuH7 and SNU449) and then we measured the resulted effect by MTT assay for cell proliferation. After treatments we investigated tumour microenvironment (vimentin, cadherin) and immune markers (PD-L1, CTLA4 and cytokines) on HuH7 and SNU449 cells co-coltured with PBMCs (peripheral blood mononuclear cells) through RT-PCR.
Results
Combination of atezolizumab and bevacizumab followed by lenvatinib shows a reduction of cell growth, we observed a decrease in cell proliferation of 53.2 and 58.1 % for HuH7 and SNU449 respectively. This result is enhanced in cell co-coltures with PBMCs, in which cell viability is significantly reduced reaching value of 37.5 and 38.2 % for HuH7 and SNU449. We observed a decrease of PD-L1 and CTLA4 and a parallel increase of IFNγ, GRZb, IL-6 and IL1β, all cytokines able to create favourable microenvironment for inflammatory and immune response. The effect is accompanied by a functional change in favour of EMT blockade with increased cadherin and reduced vimentin expression (8.26- and 0.5-fold increase values, for cadherin and vimentin respectively, compared to untreated control) after sequential treatments.
Conclusions
Our work could provide good perspectives on predictability and sensitivity to new drug combination strategies in patients with HCC resistant to immune blockade. We aim to confirm the effect of the treatment also in ex vivo human spheroids and patients derived lymphocytes co-coltures, to verify the possible synergism of PD-L1 and VEGF inhibition on cytokine secretion profile.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract